Germany’s patent system is becoming a critical arena for pharmaceutical companies, technology firms, and industrial manufacturers competing to secure intellectual property rights that will shape market leadership for years. The European Patent Office (EPO) has observed a sharp rise in patent filings and opposition proceedings, with disputes now covering diabetes treatments, solar technology, and even nuclear waste containment systems.
The most prominent conflict involves Merck Sharp & Dohme (MSD), which is opposing generic drugmakers over a supplementary protection certificate (SPC) for its diabetes medication metformin/Janumet. This certificate extends patent protection beyond the original term, potentially allowing MSD to block cheaper alternatives. Novartis and Vertex have also filed for SPCs on other drugs. Meanwhile, Kuraray is contesting a competitor’s patent revocation in a case involving PVB interlayers, a material used in laminated products.
Beyond pharmaceuticals, the EPO’s opposition cases reveal a broader trend: companies are aggressively defending patents in industries where innovation directly influences supply chains. Chemours, Clariant, DuPont, and Philip Morris are among those filing or opposing patents, often targeting materials or processes essential to their operations. For example, Wessel Werk is challenging Electrolux and LG Electronics over vacuum cleaner nozzles—a dispute that highlights how even consumer products depend on patented components.
The technology sector is equally active, with Qualcomm pursuing nullity suits against Networks Systems in telecommunications. Apple, Sony, and Dell are also involved in patent oppositions, while Brose and Kiekert remain locked in litigation over car-door lock mechanisms, a case that could influence future vehicle designs. Additionally, Tesla, TSMC, and LG Energy Solutions have filed patents in Germany, reinforcing the country’s status as a hub for electric vehicle and semiconductor innovation.
Biotech wars escalate over life-saving drugs
Biotechnology and healthcare disputes remain particularly contentious. Amgen is opposing Sanofi and Alexion over patents for cholesterol-lowering and rare-disease treatments, while Biogen is challenging Sandoz and others over Spinraza, a spinal muscular atrophy therapy. The conflicts extend to straw-man oppositions, where third parties challenge patents, targeting drugs like dupilumab (Dupixent) for atopic dermatitis and daratumumab (Darzalex) for cancer.
Related Post: German Court Blocks Polytech Manager’s Arrest in Patent Row
Germany’s courts are handling high-stakes patent cases as well. KPN is suing Oppo over standard-essential patents (SEPs) at the Federal Court of Justice, a case that could set precedents for licensing disputes in telecommunications. Meanwhile, Merck is contesting Hisense in a nullity suit over LCD dyes, a conflict that shows global competition in display technology.
The volume of filings indicates that companies view Germany as a key jurisdiction-not only for enforcing patents but also for shaping industry standards. The EPO’s opposition proceedings, which allow third parties to challenge granted patents, are active in various sectors. For instance, Symrise is opposing Stada over sunscreen formulations, while Nordson is challenging Baumer in adhesive application technology-a dispute that could affect manufacturing processes across industries.
Germany’s patent hotspots fuel global tech races
The EPO’s data shows that Berlin, Munich, Düsseldorf, and Frankfurt remain the most active locations for patent filings and oppositions, with companies ranging from Siemens Healthineers to Novo Nordisk submitting new patents in biotechnology and medical devices.
Manufacturers of industrial and specialty materials are leading a surge in patent filings. Chemours, Clariant, and DuPont remain active in opposing or filing patents related to fluoropolymers, coatings, and specialty chemicals—areas where even minor improvements can secure market dominance.
